Nicole DeMars

Stocks in Review: PBF Energy Inc. (PBF), ZAIS Group Holdings, Inc. (ZAIS), Zions Bancorporation (ZION)

PBF Energy Inc. (PBF) traded within a range of $23.96 to $24.75 after opening the day at $24.61. The company has seen its stock decrease in value by -11.91% so far this year. The stock was down close to -0.16% on active volume in last trading session and closed at $24.56 per share. After the recent fall, the stock is currently holding -28.55% below its 52 week high of $35.67 and 27.84% above its 12-month low of $19.47. The shares are down by over -6.01% in the last three months, and the RSI indicator value of 52.49 is neither bullish nor bearish, tempting investors to stay on the sidelines.

PBF Energy Inc., together with its subsidiaries, engages in the refining and supply of petroleum products. It produces gasoline, ultra-low-sulfur diesel, heating oil, diesel fuel, jet fuel, lubricants, petrochemicals, and asphalt, as well as unbranded transportation fuels, petrochemical feedstocks, blending components, and other petroleum products. The company sells its products in Northeast and Midwest of the United States, as well as in other regions of the United States and Canada. PBF Energy Inc. was founded in 2008 and is based in Parsippany, New Jersey.

ZAIS Group Holdings, Inc. (ZAIS) failed to extend gains with the stock declining -21.99% or $-0.95 to close the day at $3.37 on light trading volume of 2.72M shares, compared to its three month average trading volume of 528.66K. The Red Bank New Jersey 07701 based company has been underperforming the asset management group over the past 52 weeks, with the stock losing -48.47%, compared to the industry which has advanced 32.86% over the same period. With RSI of 66.93, the stock should still continue to rise and get closer to its one year target estimate of $0, making it a hold for now.

ZAIS Group Holdings, Inc., an investment management company, focuses on investments in specialized credit strategies. The company manages assets across mortgage-related specialized credit strategies, including residential whole loans, residential mortgage backed securities, asset backed securities, and commercial mortgage backed securities; and corporate-credit, including collateralized loan obligations, collateralized bond obligations, collateralized synthetic obligations, credit default swaps, high yield bonds, and leveraged loans. It also provides solutions to investors in structured credit. ZAIS Group Holdings, Inc. has operations in the United States, London, and Shanghai. The company was founded in 1997 and is based in Red Bank, New Jersey.

Zions Bancorporation (ZION) gained $0.22 to close the day at a new closing price of $45.3, a 0.49% increase in value from its previous closing price that moved the stock 127.65% above its 52 week low of $20.08. A total of 2.69M shares exchanged hands during the day compared with its three month average trading volume of 2.67M. The stock, which fluctuated between $45.05 and $45.52 during the day, currently situated 0.2% above its 52 week high. The stock is up by 8.65% in the past one month and up by 18.09% over the past three months. With a one year target estimate of $45.96 and RSI of 64.48, the stock still has upside potential, making it a hold for now.

Zions Bancorporation, a financial holding company, provides a range of banking and related services in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company offers community banking services, such as small and medium-sized business and corporate banking; commercial and residential development, construction, and term lending; retail banking; treasury cash management and related products and services; and residential mortgage servicing and lending. It also provides trust and wealth management services; capital markets services, including municipal finance advisory and underwriting; and investment services. In addition, the company offers personal banking services to individuals, including home mortgages, bankcards, other installment loans, home equity lines of credit, checking accounts, savings accounts, certificates of deposit of various types and maturities, safe deposit facilities, direct deposits, and Internet and mobile banking services. Further, it provides online and traditional brokerage services; small business administration and secondary market agricultural real estate mortgage loans; and bond transfer, stock transfer, and escrow services for corporate customers. As of December 31, 2015, the company operated 450 domestic branches. Zions Bancorporation was founded in 1873 and is headquartered in Salt Lake City, Utah.

 

Stock’s Trend Analysis Report: GoDaddy Inc. (GDDY), American Homes 4 Rent (AMH), PharmAthene, Inc. (PIP)

GoDaddy Inc. (GDDY) climbed 3.08% during last trading as the stock added $1.12 to finish the day at $37.46 with about 2.28M shares changing hands, compared to its three month average trading volume of 753.86K. The $6.23B market cap company, which fluctuated between $35.82 and $37.54 during the day, currently situated 48.59% above its 52 week low of $27.15 and 0.16% away from its one year high of $37.54. The RSI of 69.8 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

GoDaddy Inc. designs and develops cloud-based technology products for small businesses, Web design professionals, and individuals in the United States and internationally. The company offers domain name registration product that enables to engage customers at the initial stage of establishing a digital identity; hosting and presence products, including shared Website hosting, Website hosting on virtual dedicated servers and dedicated servers, security, and cloud services and cloud applications. It also provides Website builder, an online tool that enables customers to build Websites; online store product that allows customers to create their own standalone online store or add one to an existing Website; and search engine visibility product that helps customers get their Websites found on search sites through search engine optimization. In addition, the company offers business application products consisting of email accounts, Microsoft Office 365, and email marketing. The company was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

American Homes 4 Rent (AMH) gained $0.03 to close the day at a new closing price of $22.94, a 0.13% increase in value from its previous closing price that moved the stock 73.3% above its 52 week low of $13.22. A total of 2.28M shares exchanged hands during the day compared with its three month average trading volume of 2.22M. The stock, which fluctuated between $22.65 and $23 during the day, currently situated -0.82% below its 52 week high. The stock is up by 10.18% in the past one month and up by 12.01% over the past three months. With a one year target estimate of $23.94 and RSI of 79.62, the stock still has upside potential, making it a sell for now.

American Homes 4 Rent is a real estate investment trust. The firm engages in the acquisition, renovation, leasing, and operating single-family home rental properties in the United States. American Homes 4 Rent was founded in 2012 and is based in Malibu, California.

PharmAthene, Inc. (PIP) had a light trading with around 2.28M shares changing hands compared to its three month average trading volume of 3.9M. The stock traded between $1.06 and $1.1 before closing at the price of $1.07 with -2.73% change on the day. The Annapolis Maryland 21401 based company is currently trading 127.66% above its 52 week low of $0.47 and -69.43% below its 52 week high of $3.5. Both the RSI indicator and target price of 22.6 and $6 respectively, lead us to believe that it could rise over the coming weeks.

PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. The company focuses on developing lyophilized anthrax vaccines based on DepoVax, a proprietary technology platform that contributes recombinant protective antigen bulk drug substance. It serves National Institute of Allergy and Infectious Diseases, and the Biomedical Advanced Research and Development Authority. The company has a license agreement with ImmunoVaccine Technologies for the use of the DepoVax vaccine platform to develop an anthrax vaccine. PharmAthene, Inc. is headquartered in Annapolis, Maryland.

 

Stocks In Queue: Biostage, Inc. (BSTG), GameStop Corp. (GME), First Solar, Inc. (FSLR)

Biostage, Inc. (BSTG) fell -0.1% during last trading as the stock lost $0 to finish the day at $0.31 with about 2.15M shares changing hands, compared to its three month average trading volume of 444.53K. The $9.01M market cap company, which fluctuated between $0.305 and $0.32 during the day, currently situated 6.26% above its 52 week low of $0.2925 and -89.13% away from its one year high of $2.8599. The RSI of 17 indicates the stock is oversold at the current levels, buy for now.

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company’s Cellframe technology combines a proprietary biocompatible scaffold with a patient’s own stem cells to create Cellspan organ implants. The company is developing bioengineered organ implants to treat cancers, infection, trauma, congenital abnormalities, and other life-threatening conditions of the esophagus, bronchus, and trachea. Its implants are being advanced and tested in a preclinical collaborative study with Mayo Clinic. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

GameStop Corp. (GME) gained $0.04 to close the day at a new closing price of $25.78, a 0.16% increase in value from its previous closing price that moved the stock 30.17% above its 52 week low of $20.1. A total of 2.15M shares exchanged hands during the day compared with its three month average trading volume of 2.45M. The stock, which fluctuated between $25.54 and $26.08 during the day, currently situated -20.35% below its 52 week high. The stock is up by 10.45% in the past one month and up by 13.81% over the past three months. With a one year target estimate of $26.32 and RSI of 63.45, the stock still has upside potential, making it a hold for now.

GameStop Corp. operates as an omnichannel video game retailer. It sells new and pre-owned video game hardware; physical and digital video game software; pre-owned and value video game products; video game accessories, such as controllers, gaming headsets, memory cards, and other add-ons for use with video game hardware and software; and digital products, including downloadable content, network points cards, prepaid digital and subscription cards, and digitally downloadable software. The company also sells mobile and consumer electronics, including smart phones, tablets, headphones, and accessories, as well as pre-owned smart phones; personal computer (PC) entertainment software in various genres, including sports, action, strategy, adventure/role playing, and simulation; and strategy guides, magazines, and gaming-related toys. In addition, it operates electronic commerce Websites comprising gamestop.com, ebgames.com.au, ebgames.co.nz, gamestop.ca, gamestop.it, gamestop.ie, gamestop.de, gamestop.co.uk, thinkgeek.com, and micromania.fr. Further, the company operates kongregate.com, a browser-based game site; Game Informer magazine, a print and digital video game publication; iOS and Android mobile applications; Simply Mac, a certified Apple consumer electronic products reseller; and Spring Mobile, an authorized AT&T reseller operating pre-paid wireless stores under the Cricket Wireless name that offers prepaid services, devices, and accessories. As of January 30, 2016, it operated approximately 7,117 stores in the United States, Australia, Canada, and Europe. GameStop Corp. primarily offers its products under the GameStop, EB Games, and Micromania names. The company, formerly known as GSC Holdings Corp., was founded in 1994 and is headquartered in Grapevine, Texas.

First Solar, Inc. (FSLR) had a light trading with around 2.13M shares changing hands compared to its three month average trading volume of 2.47M. The stock traded between $33.73 and $34.82 before closing at the price of $34.73 with 2.39% change on the day. The Tempe Arizona 85281 based company is currently trading 21.43% above its 52 week low of $28.6 and -53.25% below its 52 week high of $74.29. Both the RSI indicator and target price of 62.84 and $34.1 respectively, lead us to believe that it should be put on hold over the coming weeks.

First Solar, Inc. provides solar energy solutions in the United States and internationally. It operates through two segments, Components and Systems. The Components segment designs, manufactures, and sells solar modules that convert sunlight into electricity. This segment manufactures cadmium telluride and crystalline silicon modules for system integrators and operators. The Systems segment provides turn-key photovoltaic solar power systems or solar solutions, such as project development; engineering, procurement, and construction; and operating and maintenance services to utilities, independent power producers, and commercial and industrial companies. It also commissions a 52.5 megawatt Shams Ma’an solar power plant in the Hashemite Kingdom of Jordan. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona.

 

Stocks To Track: PDL BioPharma, Inc. (PDLI), Moleculin Biotech, Inc. (MBRX), STORE Capital Corporation (STOR)

PDL BioPharma, Inc. (PDLI) fell -0.87% during last trading as the stock lost $-0.02 to finish the day at $2.29 with about 1.8M shares changing hands, compared to its three month average trading volume of 2.8M. The $374.09M market cap company, which fluctuated between $2.24 and $2.32 during the day, currently situated 18.65% above its 52 week low of $1.93 and -39.49% away from its one year high of $3.84. The RSI of 58.75 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Moleculin Biotech, Inc. (MBRX) gained $0.12 to close the day at a new closing price of $1.33, a 9.92% increase in value from its previous closing price that moved the stock 15.65% above its 52 week low of $1.15. A total of 1.79M shares exchanged hands during the day compared with its three month average trading volume of 206.16K. The stock, which fluctuated between $1.19 and $1.39 during the day, currently situated -86.12% below its 52 week high. The stock is down by -43.16% in the past one month and down by -51.28% over the past three months. With a one year target estimate of $9.26 and RSI of 38.17, the stock still has upside potential, making it a hold for now.

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

STORE Capital Corporation (STOR) had a active trading with around 1.79M shares changing hands compared to its three month average trading volume of 1.35M. The stock traded between $23.78 and $24.07 before closing at the price of $23.99 with -0.62% change on the day. The Scottsdale Arizona 85255 based company is currently trading 4.76% above its 52 week low of $22.9 and -22.01% below its 52 week high of $31.44. Both the RSI indicator and target price of 46.38 and $28.68 respectively, lead us to believe that it should be put on hold over the coming weeks.

STORE Capital Corporation is a privately owned real estate investment trust. The firm invests in the real estate markets. It primarily invests in single-tenant properties including chain restaurants, supermarkets, drugstores and other retail, service and distribution facilities. It was formerly known as STORE Capital. STORE Capital Corporation is based in Scottsdale, Arizona.

 

3 Notable Runners: Cellectar Biosciences, Inc. (CLRB), Take-Two Interactive Software, Inc. (TTWO), Starwood Property Trust, Inc. (STWD)

Cellectar Biosciences, Inc. (CLRB) continued its upward trend with the stock climbing 6.41% or $0.15 to close the day at $2.49 on lower than average trading volume of 1.67M shares, compared to its three month average trading volume of 880.75K. The Madison Wisconsin 53716 based company has been outperforming the biotechnology companies by 33.8238% for last three months and its recent gains have pushed the stock slightly up 104.1% YTD, versus the biotechnology industry which is up 0.44% for the same period. The RSI of 85.55 indicates the stock is overbought at the current levels, sell for now.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Take-Two Interactive Software, Inc. (TTWO) had a active trading with around 1.66M shares changing hands compared to its three month average trading volume of 1.33M. The stock traded between $57.85 and $59.56 before closing at the price of $59.44 with 2.03% change on the day. The New York New York 10012 based company is currently trading 79.79% above its 52 week low of $33.06 and 1.16% above its 52 week high of $59.56. Both the RSI indicator and target price of 80.38 and $59.94 respectively, lead us to believe that it could drop over the coming weeks.

Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment solutions for consumers worldwide. The company offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels; offering downloadable episodes, and content and virtual currency; and releasing titles for smartphones and tablets. The company also develops brands in other genres, including the L.A. Noire, Bully, and Manhunt franchises. In addition, it publishes various entertainment properties across platforms and a range of genres, including action, adventure, family/casual, racing, role-playing, shooter, sports, and strategy; various unit selling franchises, including BioShock, Borderlands, Carnival Games, Evolve, Mafia, NBA 2K, Sid Meier’s Civilization, Spec Ops, WWE 2K, and XCOM; and various sports simulation titles, including its flagship NBA 2K series, a basketball video game and the WWE 2K professional wrestling series. Further, the company offers free-to-play mobile games, such as Dragon City and Monster Legends on iOS and Android platforms. Its products are designed for console gaming systems, such as Sony’s PlayStation 3 and PlayStation 4, and Microsoft’s Xbox 360 and Xbox One; and personal computers comprising smartphones and tablets. The company delivers its products through physical retail, digital download, online platforms, and cloud streaming services. Take-Two Interactive Software, Inc. was founded in 1993 and is headquartered in New York, New York.

Starwood Property Trust, Inc. (STWD) traded within a range of $22.56 to $22.81 after opening the day at $22.78. The company has seen its stock increase in value by 3.14% so far this year. The stock was down close to -0.75% on light volume in last trading session and closed at $22.64 per share. After the recent fall, the stock is currently holding -1.26% below its 52 week high of $23.46 and 45.54% above its 12-month low of $17.29. The shares are up by over 8.63% in the last three months, and the RSI indicator value of 59.95 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Starwood Property Trust, Inc. originates, acquires, finances, and manages commercial mortgage loans, other commercial real estate debt investments, commercial mortgage-backed securities, and other commercial real estate- investments in the United States and Europe. It operates through three segments: Real Estate Lending, Real Estate Investing and Servicing, and Real Estate Property. The company qualifies as a real estate investment trust for federal income tax purposes and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. Starwood Property Trust, Inc. was founded in 2009 and is headquartered in Greenwich, Connecticut.

 

Eye Catching Stocks: Axalta Coating Systems Ltd. (AXTA), Anavex Life Sciences Corp. (AVXL), Gigamon Inc. (GIMO)

Axalta Coating Systems Ltd. (AXTA) continued its upward trend with the stock climbing 1.08% or $0.32 to close the day at $29.98 on light trading volume of 1.61M shares, compared to its three month average trading volume of 2.11M. The Philadelphia Pennsylvania 19103 based company has been outperforming the specialty chemicals group over the past 52 weeks, with the stock gaining 19.78%, compared to the industry which has advanced 33.12% over the same period. With RSI of 73.23, the stock should still continue to rise and get closer to its one year target estimate of $31.44, making it a hold for now.

Axalta Coating Systems Ltd., through its subsidiaries, manufactures, markets, and distributes high performance coatings products primarily for the transportation industry. It operates through two segments, Performance Coatings and Transportation Coatings. The Performance Coatings segment offers various waterborne and solventborne products and systems that are used to refinish damaged vehicles for independent body shops, multi-shop operators, and original equipment manufacturer (OEM) dealership body shops. This segment also provides functional and decorative liquid and powder coatings for use in various industrial applications, including architectural cladding and fittings, automotive coatings, general industrial, job coaters, electrical insulation coatings, HVAC, appliances, rebar, and oil and gas pipelines. It offers liquid coatings under the Voltatex, AquaEC, Chemophan, Lutophen, Stollaquid, and Syntopal brand names; and powder coatings under the brand names of Alesta, Nap-Gard, and Abcite. This segment sells and supplies its products directly to customers, as well as through a network of independent local distributors. The Transportation Coatings segment develops and supplies a line of coatings products, such as electrocoat, primer, basecoat, and clearcoat products for light vehicle OEMs for the coating of new vehicles; and various coatings systems for various commercial applications, including heavy-duty truck, bus, rail, and agricultural construction equipment. It sells and ships its products directly to light vehicle OEM customers. Axalta Coating Systems Ltd. has operations in North America; Europe, the Middle East, and Africa; the Asia Pacific; and Latin America. The company was formerly known as Axalta Coating Systems Bermuda Co., Ltd. and changed its name to Axalta Coating Systems Ltd. in August 2014. Axalta Coating Systems Ltd. was founded in 1866 and is headquartered in Philadelphia, Pennsylvania.

Anavex Life Sciences Corp. (AVXL) climbed 1.31% during last trading as the stock added $0.08 to finish the day at $6.21 with about 1.61M shares changing hands, compared to its three month average trading volume of 846.69K. The $256.41M market cap company, which fluctuated between $5.95 and $6.64 during the day, currently situated 155.56% above its 52 week low of $2.43 and -25.18% away from its one year high of $8.3. The RSI of 89.94 indicates the stock is overbought at the current levels, sell for now.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer’s disease, other central nervous system diseases, pain, and various cancers. The company’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer’s disease; and preclinical stage to treat Parkinson’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Gigamon Inc. (GIMO) saw its value increase by 2.95% as the stock gained $1 to finish the day at a closing price of $34.95. The stock was higher in trading and has fluctuated between $23.5-$61.25 per share for the past year. The shares, which traded within a range of $33.55 to $35.85 during the day, are down by -39.11% in the past three months and down by -23.22% over the past six months. It is currently trading 7.08% above its 20 day moving average and -14.96% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $36.36 a share over the next twelve months. The current relative strength index (RSI) reading is 47.1. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gigamon Inc. designs, develops, and sells products and services that provide customers with visibility and control of network traffic for enterprises and services providers in the United States, rest of Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers traffic visibility fabric solutions consisting of network traffic intelligence, such as controls for traffic selection, forwarding, manipulation, modification, de-duplication, SSL decryption, correlation, sampling, and generation of flow records. The company also provides Flow Mapping technology that identifies and directs incoming traffic to single or various tools based on user-defined rules that could be managed from a centralized management console; and GigaSMART platform, which offers a range of software applications to modify, manipulate, transform, filter, correlate, and sample network traffic. Its products include GigaVUE product family that provides end-user customers to design visibility fabric architectures optimized for a range of scale and performance requirements from monitoring in virtualized server environments, as well as to 1 gigabit appliances to multi-terabit chassis-based solutions. The company also offers ongoing technical support services with hardware and software products, including ongoing maintenance services for hardware and software, which enable the customers to receive ongoing software updates, bug fixes, and repairs; and replacement services for defective hardware. It sells its products directly through direct sales force and a network of channel partners. The company was founded in 2004 and is headquartered in Santa Clara, California.

 

Stocks Alert: LightPath Technologies, Inc. (LPTH), Stage Stores, Inc. (SSI), Sucampo Pharmaceuticals, Inc. (SCMP)

LightPath Technologies, Inc. (LPTH) retreated with the stock falling -5.45% or $-0.12 to close at $2.08 on light trading volume of 1.49M compared its three months average trading volume of 224.22K. The Orlando Florida 32826 based company operating under the Industrial Electrical Equipment industry has been trending down for the last 52 weeks, with the shares price now -3.7% down for the period and up by 35.06% so far this year. With price target of $2.5 and a 71.9% rebound from 52-week low, LightPath Technologies, Inc. has plenty of upside potential, making it a hold with a view buy.

LightPath Technologies, Inc. designs, develops, manufactures, and distributes optical components and assemblies. The company offers precision molded glass aspheric optics, infrared aspheric lenses, GRADIUM glass lenses, and other optical materials used to produce products that manipulate light. Its products are used in various industries, including defense products, medical devices, laser aided industrial tools, automotive safety applications, barcode scanners, optical data storage, hybrid fiber coax datacom, telecommunications, machine vision and sensors, and other industries. The company sells its products directly to customers in North America and China, as well as through distributors and channel partners in Europe, the United States, and internationally. LightPath Technologies, Inc. was founded in 1985 and is headquartered in Orlando, Florida.

Stage Stores, Inc. (SSI) gained $0.01 to close the day at a new closing price of $2.53, a 0.4% increase in value from its previous closing price that moved the stock 10.96% above its 52 week low of $2.28. A total of 1.49M shares exchanged hands during the day compared with its three month average trading volume of 1.11M. The stock, which fluctuated between $2.49 and $2.56 during the day, currently situated -69.31% below its 52 week high. The stock is down by -25.15% in the past one month and down by -53% over the past three months. With a one year target estimate of $2.33 and RSI of 33.02, the stock still has upside potential, making it a hold for now.

Stage Stores, Inc. operates as a specialty department store retailer in small and mid-sized towns and communities in the United States. Its merchandise portfolio comprises moderately priced brand name and private label apparel, accessories, cosmetics, footwear, and home goods. The company also offers merchandise direct-to-consumer through its e-commerce Website and send program. As of January 30, 2016, it operated 834 specialty department stores in 39 states and a direct-to-consumer channel under the BEALLS, GOODY’S, PALAIS ROYAL, PEEBLES, and STAGE nameplates. The company was founded in 1988 and is headquartered in Houston, Texas.

Sucampo Pharmaceuticals, Inc. (SCMP) shares were up in last trading by 2.98% to $12.1. It experienced higher than average volume on day. The stock increased in value by almost 4.31% over the past week and grew 2.54% in the past month. It is currently trading -7.16% below its 50 day moving average and -2.11% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -31.05% decrease in value from its one year high of $17.55. The RSI indicator value of 50.77, lead us to believe that it is a hold for now.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product candidates, which are in clinical development stage comprise Cobiprostone that is in Phase IIa trials for the treatment of oral mucositis, non-erosive reflux, and symptomatic gastroesophageal reflux diseases; RTU-1096, which has completed Phase I trial for treating inflammation/immune-related disorders; and RTU-009 that is in development stage for inflammation/immune-related disorders, as well as CPP-1X/sulindac combination product, which is in phase III clinical trial for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals, Inc. is a subsidiary of S&R Technology Holdings, LLC.

 

Stocks In Action: Marinus Pharmaceuticals, Inc. (MRNS), AVEO Pharmaceuticals, Inc. (AVEO), Patterson Companies, Inc. (PDCO)

Marinus Pharmaceuticals, Inc. (MRNS) traded within a range of $1.26 to $1.37 after opening the day at $1.29. The company has seen its stock increase in value by 35.64% so far this year. The stock was up close to 6.2% on light volume in last trading session and closed at $1.37 per share. After the recent gain, the stock is currently holding -79.73% below its 52 week high of $6.76 and 66.81% above its 12-month low of $0.82. The shares are up by over 16.1% in the last three months, and the RSI indicator value of 67.34 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

AVEO Pharmaceuticals, Inc. (AVEO) continued its upward trend with the stock climbing 15.09% or $0.11 to close the day at $0.84 on light trading volume of 1.36M shares, compared to its three month average trading volume of 284.39K. The Cambridge Massachusetts 02142 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -12.11%, compared to the industry which has advanced 0.95% over the same period. With RSI of 76.43, the stock should still continue to rise and get closer to its one year target estimate of $2.38, making it a hold for now.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company’s pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Patterson Companies, Inc. (PDCO) gained $0.01 to close the day at a new closing price of $43.5, a 0.02% increase in value from its previous closing price that moved the stock 20% above its 52 week low of $36.46. A total of 1.36M shares exchanged hands during the day compared with its three month average trading volume of 1.77M. The stock, which fluctuated between $42.67 and $43.57 during the day, currently situated -12.31% below its 52 week high. The stock is up by 6.02% in the past one month and down by -8.62% over the past three months. With a one year target estimate of $41.85 and RSI of 72.48, the stock still has upside potential, making it a sell for now.

Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. The company’s Dental Supply segment offers dental products, including consumable products, such as infection control, restorative materials, hand instruments, and sterilization products; basic and advanced technology dental equipment; patient education systems; and office forms and stationery. This segment also develops and sells technology solutions, such as practice management software and e-commerce solutions. In addition, it offers a range of related services, including software and design services, maintenance and repair, and equipment financing. The company’s Animal Health Supply segment distributes animal health products, such as pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. This segment also offers a range of value-added services to animal health customers. The company’s customers include dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in St. Paul, Minnesota.

 

3 Stocks in Focus: Gilead Sciences Inc. (GILD), General Motors Company (GM), Baxter International Inc. (BAX)

Gilead Sciences Inc. (GILD) fell -0.15% during last trading as the stock lost $-0.1 to finish the day at $67.55 with about 14.91M shares changing hands, compared to its three month average trading volume of 10.34M. The $88.9B market cap company, which fluctuated between $67.33 and $68.67 during the day, currently situated 3.32% above its 52 week low of $65.38 and -33.29% away from its one year high of $103.1. The RSI of 35.55 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

General Motors Company (GM) gained $1.72 to close the day at a new closing price of $37.24, a 4.84% increase in value from its previous closing price that moved the stock 40.72% above its 52 week low of $27.05. A total of 31.23M shares exchanged hands during the day compared with its three month average trading volume of 14.16M. The stock, which fluctuated between $36.67 and $37.4 during the day, currently situated -2.97% below its 52 week high. The stock is down by -0.27% in the past one month and up by 10.65% over the past three months. With a one year target estimate of $38.82 and RSI of 56.83, the stock still has upside potential, making it a hold for now.

General Motors Company designs, builds, and sells cars, trucks, crossovers, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Holden, Opel, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars, trucks, and crossovers to dealers for consumer retail sales, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its subsidiary, General Motors Financial Company, Inc., provides automotive financing services. General Motors Company was founded in 1897 and is based in Detroit, Michigan.

Baxter International Inc. (BAX) had a light trading with around 2.74M shares changing hands compared to its three month average trading volume of 3.36M. The stock traded between $48.77 and $49.31 before closing at the price of $48.96 with -0.55% change on the day. The Deerfield Illinois 60015 based company is currently trading 35.07% above its 52 week low of $37.36 and -2.11% below its 52 week high of $50.16. Both the RSI indicator and target price of 69.23 and $52.88 respectively, lead us to believe that it should be put on hold over the coming weeks.

Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

 

Stocks Alert: Vonage Holdings Corp. (VG), Rent-A-Center, Inc. (RCII), Helix Energy Solutions Group, Inc. (HLX)

Vonage Holdings Corp. (VG) retreated with the stock falling -0.87% or $-0.06 to close at $6.8 on active trading volume of 7.58M compared its three months average trading volume of 2.43M. The Holmdel New Jersey 07733 based company operating under the Diversified Communication Services industry has been trending up for the last 52 weeks, with the shares price now 38.78% up for the period and down by -0.73% so far this year. With price target of $8.67 and a 78.01% rebound from 52-week low, Vonage Holdings Corp. has plenty of upside potential, making it a hold with a view buy.

Vonage Holdings Corp. provides communications services connecting people through cloud-connected devices worldwide. It offers various business services, including basic dial tone, call queue, conferencing, call groups, mobile functionality, CRM integration, and detailed analytics, as well as Vonage Essential services. The company also provides home telephone replacement services through various service plans with basic features, such as voicemail, call waiting, call forwarding, simulring, visual voicemail, and extensions, as well as area code selection, virtual phone number, and Web-enabled voicemail. Its primary home telephone offering is Vonage World that offers unlimited domestic calling; calling to landline phones in approximately 60 countries; and calling to mobile phones in various countries. mobile services, including Vonage Mobile, a mobile application that provides free calling and messaging between users who have the application, as well as international calling to other phone; and Vonage-enabled devices, which allow customers to use the Internet connection for their computer and telephones at the same time. Further, it offers high-speed broadband Internet service that allows calls over the Internet either from a telephone through a Vonage-enabled device, or through soft phone software, or mobile client applications. The company sells its products through its sales agents, Websites, toll free numbers, and regional and national retailers for consumers and businesses in the United States, the United Kingdom, and Canada. As of December 31, 2015, it had approximately 2.5 million consumer subscriber lines and business seats. The company was incorporated in 2000 and is headquartered in Holmdel, New Jersey.

Rent-A-Center, Inc. (RCII) dropped $-0.47 to close the day at a new closing price of $7.98, a -5.56% decrease in value from its previous closing price that moved the stock 2.84% above its 52 week low of $7.76. A total of 7.37M shares exchanged hands during the day compared with its three month average trading volume of 1.58M. The stock, which fluctuated between $7.93 and $8.9 during the day, currently situated -50% below its 52 week high. The stock is down by -23.2% in the past one month and down by -31.71% over the past three months. With a one year target estimate of $9.67 and RSI of 29.16, the stock still has upside potential, making it a buy for now.

Rent-A-Center, Inc., together with its subsidiaries, leases household durable goods to customers on a rent-to-own basis. The company operates through four segments: Core U.S., Acceptance Now, Mexico, and Franchising. It offers durable products, such as consumer electronics; appliances; computers, including tablets; smartphones; and furniture, including accessories under rental purchase agreements. The company also provides merchandise on an installment sales basis; and offers the rent-to-own transaction to consumers who do not qualify for financing from the traditional retailer through kiosks within retailer’s locations. It operates retail installment sales stores under the Get It Now and Home Choice names; and rent-to-own and franchised rent-to-own stores under the Rent-A-Centre, ColorTyme, and RimTyme names. As of December 31, 2015, the company owned and operated approximately 2,672 stores in the United States, Canada, and Puerto Rico, including 45 retail installment sales stores; 1,444 Acceptance Now kiosk locations in 40 states and Puerto Rico; 532 Acceptance Now direct locations; and 143 stores in Mexico, as well as franchised 227 rent-to-own stores in 31 states under the Rent-A-Center, ColorTyme, and RimTyme names. Rent-A-Center, Inc. was founded in 1986 and is headquartered in Plano, Texas.

Helix Energy Solutions Group, Inc. (HLX) shares were up in last trading by 9.48% to $8.2. It experienced higher than average volume on day. The stock increased in value by almost 7.05% over the past week and fell -3.3% in the past month. It is currently trading -10.46% below its 50 day moving average and -1.47% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -30.92% decrease in value from its one year high of $11.87. The RSI indicator value of 47.29, lead us to believe that it is a hold for now.

Helix Energy Solutions Group, Inc., together with its subsidiaries, provides specialty services to the offshore energy industry primarily in the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions. It operates through three segments: Well Intervention, Robotics, and Production Facilities. The company engineers, manages, and conducts well construction, intervention, and abandonment operations in water depths ranging from 200 to 10,000 feet; and operates remotely operated vehicles (ROVs), trenchers, and ROVDrills for offshore construction, maintenance, and well intervention services. It also offers well intervention; intervention engineering; production enhancement; inspection, repair, and maintenance of production structures, trees, jumpers, risers, pipelines, and subsea equipment; and life of field support. In addition, the company provides reclamation and remediation services; well plugging and abandonment services; pipeline abandonment services; and site inspections. Further, it engages in the installation of subsea pipelines, flowlines, control umbilicals, manifold assemblies, and risers; burial of pipelines; installation and tie-in of riser and manifold assembly; commissioning, testing, and inspection activities; and provision of cable and umbilical lay, and connection services. Additionally, the company offers oil and natural gas processing services to oil and natural gas companies; and fast response system services. It serves independent oil and gas producers and suppliers, pipeline transmission companies, alternative energy companies, and offshore engineering and construction firms. The company was formerly known as Cal Dive International, Inc. and changed its name to Helix Energy Solutions Group, Inc. in March 2006. Helix Energy Solutions Group, Inc. was incorporated in 1979 and is headquartered in Houston, Texas.